Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, People's Republic of China.
Ministry of Education, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Chengdu, People's Republic of China.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2396710. doi: 10.1080/21645515.2024.2396710. Epub 2024 Aug 28.
Human papillomavirus (HPV) has been linked to the development of various cancers, including head and neck, cervical, vaginal, penile, and anal cancers. The development of therapeutic vaccines against HPV-positive tumors is crucial for protecting individuals already infected with HPV, preventing tumor progression, and effectively treating the disease. The HPV therapeutic peptide-based vaccines demonstrate specificity and safety advantages by targeting specific epitopes while minimizing the risk of allergic or autoimmune reactions. However, HPV therapeutic peptide-based vaccines typically lack immunogenicity and frequently fail to induce effective immune responses. Therefore, there is a need for more effective approaches to improve the immunogenicity of HPV peptide-based vaccines. Here, we review relevant research and possible uses for increasing the immunogenicity and therapeutic efficacy of HPV peptide-based vaccines through combined therapy and improved delivery strategies. Additional research is necessary to validate the application of combination therapy and delivery strategy modifications as standard treatment approaches for HPV therapeutic peptide-based vaccines.
人乳头瘤病毒（HPV）与多种癌症的发展有关，包括头颈部、宫颈、阴道、阴茎和肛门癌。开发针对 HPV 阳性肿瘤的治疗性疫苗对于保护已经感染 HPV 的个体、预防肿瘤进展和有效治疗疾病至关重要。基于 HPV 治疗性肽的疫苗通过靶向特定表位，同时最大限度地降低过敏或自身免疫反应的风险，具有特异性和安全性优势。然而，基于 HPV 的治疗性肽疫苗通常缺乏免疫原性，并且经常不能诱导有效的免疫反应。因此，需要更有效的方法来提高 HPV 肽疫苗的免疫原性。在这里，我们回顾了相关的研究，并探讨了通过联合治疗和改进的递送策略来提高 HPV 肽疫苗的免疫原性和治疗效果的可能用途。需要进一步的研究来验证联合治疗和递送策略修改作为 HPV 治疗性肽疫苗标准治疗方法的应用。
